CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 15,817	$ 12,346
Marketable debt securities	2,505	3,047
Receivables	8,290	7,685
Inventories	2,836	4,293
Other current assets	2,405	1,983
Total current assets	31,853	29,354
Property, plant and equipment	6,112	6,252
Goodwill	22,452	22,488
Other intangible assets	61,666	63,969
Deferred income taxes	605	510
Marketable debt securities	651	767
Other non-current assets	5,946	6,604
Total Assets	129,285	129,944
Current Liabilities:
Short-term debt obligations	3,862	3,346
Accounts payable	3,069	2,445
Other current liabilities	12,301	12,513
Total Current Liabilities	19,232	18,304
Accrued Income Taxes, Noncurrent	6,531	6,454
Other non-current liabilities	10,701	10,101
Long-term debt	42,844	43,387
Total Liabilities	79,308	78,246
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	43,254	43,709
Accumulated other comprehensive loss	(1,549)	(1,520)
Retained earnings	32,671	34,474
Less cost of treasury stock	(24,757)	(25,357)
Total Bristol-Myers Squibb Company Shareholders' Equity	49,911	51,598
Stockholders' Equity Attributable to Noncontrolling Interest	66	100
Total Equity	49,977	51,698
Total Liabilities and Equity	$ 129,285	$ 129,944